Membrane Sweeping to Prevent Post-term Pregnancy: The MILO Study

Pregnancy Related Clinical Trial

— MILO  

Official title:

Feasibility Study Protocol of a Pragmatic, Randomised Controlled Pilot Trial: Membrane Sweeping to Prevent Post-term Pregnancy: The MILO Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04307199
• Other study ID #: NUIreland - MILO
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 30, 2020
• Est. completion date: December 30, 2021

Study information

• Verified date: May 2020
• Source: National University of Ireland, Galway, Ireland
• Contact: Elaine M Finucane, BSc
• Phone: +353 91 495938
• Email: Elainemay.finucane[@]nuigalway.ie
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicentre, pragmatic, parallel group, pilot randomised controlled trial with an embedded factorial design.

Description:

The primary aim of the MILO study is to inform the optimal design of a future definitive randomised trial to evaluate the effectiveness (including optimal timing and frequency) of membrane sweeping to prevent post-term pregnancy. We will also assess the acceptability and feasibility of the proposed trial interventions to clinicians and women (through focus group interviews).

Methods/Design

Multicentre, pragmatic, parallel group, pilot randomised controlled trial with an embedded factorial design. Pregnant women with a live, singleton fetus ≥ 38 weeks gestation, cephalic presentation, longitudinal lie, intact membranes, English speaking and ≥18 years of age will be randomised in a 2:1 ratio to:

• Membrane sweep versus no membrane sweep

Women allocated randomly to a sweep will then be randomised further (factorial component) to:

• early (from 39 weeks) versus late (from 40 weeks) sweep commencement; and

• a single verses weekly sweep

The proposed feasibility study consists of four work packages i.e., (1) a multicentre, pilot randomised trial, 2) a health economic analysis and 3) a qualitative study (4) a study within the host trial (a SWAT).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 132
• Est. completion date: December 30, 2021
• Est. primary completion date: March 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pregnant women carrying a live singleton fetus = 38 weeks completed gestation.

• (Gestational age will be calculated from the first day of the last menstrual period and an

• ultrasound examination carried out in the 2nd trimester)

• Longitudinal lie

• Cephalic presentation

• Intact amniotic

• = 18 years of age on enrollment

Exclusion Criteria:

• Not able to communicate in english

• contraindications to a vaginal examination

• contraindications to a vaginal birth

Related Conditions & MeSH terms

• Induced; Birth
• Pregnancy Related
• Pregnancy, Prolonged

Intervention

Procedure:
• Amniotic membrane sweep
Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
National University of Ireland, Galway, Ireland	Health Research Board, Ireland

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment	Evaluation of the number and percentage of eligible women who are recruited and randomised to the study. Assessed by study-specific checklists.	Duration of the recruitment process (approximately 8 months )
Primary	Retention	Evaluation of the number and percentage of eligible women who are randomised, take part in and adhere to the study protocols. Data will be extracted from routinely collected data.	At month 15 approximately
Primary	Adherence with the trial interventions.	Evaluation of adherence with the trial interventions, and reasons for non-compliance assessed by study-specific checklists. Data will be extracted from routinely collected data and focus group interviews with clinicians and participants at six weeks post intervention.	At month 15 approximately
Primary	Evaluation of the randomisation process.	Evaluation of effective allocation of participants to the intervention/control group assessed by study-specific checklists and evaluation of the randomisation protocol throughout the randomisation period.	At month 15 approximately
Primary	Evaluation of attrition rates	Evaluation of attrition rates assessed by study-specific checklists. Data will be extracted from routinely collected data.	At month 15 approximately
Primary	Evaluation of the types of attrition	Evaluation of the types of attrition assessed by case report forms. Data will be extracted from routinely collected data.	At month 21 approximately
Primary	Evaluation of the data collection process through study specific checklists	Evaluated, statistically and narratively, by assessing the completeness of outcome measurements at baseline and postnatal (6 weeks) through study specific checklists. Researchers will manually examine the data collected. They will assess the proportion of complete data collection forms, the quality of data collected and the applicability of this data in facilitating pilot trial outcomes.	At month 21 approximately
Primary	Estimate the main effect of individual intervention components and their interactions	Estimates (with measures of uncertainty) of the main effect of individual intervention components and any interaction effect between the main effects of the embedded factorial design will be assessed and reported using regression analysis.	At month 21 approximately
Primary	Evaluation of the data analysis process	As this is a feasibility study formal hypothesis testing will not be undertaken. Researchers will manually examine the data collected. Evaluation of the data analysis process will be undertaken through the assessment of gaps and limitations to the analysis process measured by study-specific checklist. Findings will be reported through descriptive statistics and graphical summaries.	At month 21 approximately
Primary	Evaluation of the EQ5D	Assessment of the mechanism of, timing of and delivery of the EQ5D through study specific checklists.	At month 21 approximately
Primary	Feasibility of cost analyses process through analysis of study specific documentation.	Assessment of data collection tools to undertake cost effectiveness analysis through study specific documentation. Researchers will manually examine data to assess the mechanism of, timing of and delivery of the cost analysis tools.	At month 21 approximately
Primary	Feasibility of the cost effectiveness analyses	Assessment of the mechanism and utilisation of the incremental cost-effectiveness ratio (ICER), through study specific checklists.	At month 21 approximately
Secondary	Number of participants achieving a spontaneous onset of labour	Labour which begins spontaneously.	From time of randomisation to commencement of spontaneous onset of labour or formal induction of labour or caesarean section (up to 5 weeks)
Secondary	Number of participants who underwent an induction of labour	Formal induction of labour using pharmacological or surgical methods.	From time of randomisation to commencement of formal induction of labour (up to 5 weeks).
Secondary	Number of participants achieving a spontaneous vaginal birth	Spontaneous vaginal birth	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	Instrumental birth	Vaginal birth which is assisted with the use of instruments.	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	Caesarean Section	Birth which is achieved through the surgical procedure caesarean section.	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	Post-Partum Haemorrhage = 500mls	Blood loss = 500mls within the first 24 hours of the birth of a baby	From time of birth to 24 hours after the birth of baby.
Secondary	Antepartum haemorrhage requiring hospital admission	Bleeding from the genital tract, from 24+0 weeks of pregnancy and before the birth of the baby.	From 24+0 weeks of pregnancy to birth of baby (up to 18 weeks)
Secondary	Uterine hyperstimulation with/without fetal heart rate (FHR) changes	Uterine hyperstimulation defined as uterine tachysystole (more than five contractions per ten minutes for at least twenty minutes) and uterine hypersystole/hypertonicity (a contraction lasting at least two minutes). These may or not be associated with changes in the fetal heart rate pattern (persistent decelerations, tachycardia or decreased short term variability.	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	Serious maternal death or morbidity	Serious maternal death or morbidity (e.g. uterine rupture, admission to intensive care unit, septicaemia)	From time of randomisation to six weeks postnatal (up to 11 weeks).
Secondary	Epidural analgesia	Introduction of a local anaesthetic into the epidural space of the vertebral canal.	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	Augmentation of labour	The stimulation of uterine contractions using pharmacologic methods or artificial rupture of membranes to increase their frequency and/or strength following the onset of spontaneous labor or contractions following spontaneous rupture of membranes (ACOG 2014)	From commencement of established labour to birth of baby (up to 2 days)
Secondary	Pyrexia in labour	Pyrexia that developed anytime after onset of labour.	From commencement of established labour to birth of baby (up to 2 days)
Secondary	Uterine rupture	All clinically signi?cant ruptures of unscarred or scarred uteri. Trivial scar dehiscence noted incidentally at the time of surgery will be excluded	From time of randomisation to birth of baby (up to 5 weeks)
Secondary	EQ5D-5L	EuroQol EQ5D-5L survey instrument.	From time of randomisation to six weeks postnatal (up to 11 weeks)
Secondary	Serious neonatal morbidity	e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood, Proven and suspected neonatal sepsis	From time of birth of baby to six weeks postnatal.
Secondary	Apgar score < 7 at five minutes.	The Apgar score provides an accepted and convenient method for reporting the status of the newborn infant immediately after birth and the response to resuscitation if needed (ACOG 2015).	From birth of baby to five minutes of life.
Secondary	Cord PH < 7.20	Umbilical cord blood gas test.	From birth of infant to collection of cord bloods after delivery of the placenta (an average of 15 minutes)
Secondary	Neonatal encephalopathy	Severity of hypoxic ischaemic encephalopathy assessed using Sarnat staging; i)Stage 1 (mild): hyper-alertness, hyper-reflexia, dilated pupils, tachycardia, absence of seizures; ii)Stage 2 (moderate): lethargy, hyper-reflexia, miosis, bradycardia, seizures, hypotonia with weak suck and Moro reflexes; iii)Stage 3 (severe): stupor, flaccidity, small to mid-position pupils which react poorly to light, decreased stretch reflexes, hypothermia and absent Moro reflex.	From time of birth to six weeks postnatal.
Secondary	Perinatal death	The perinatal period is defined as "commences at 22 completed weeks (154 days) of gestation and ends seven completed days after birth of baby."	From time of randomisation to seven completed days after birth of baby (up to 6 weeks)
Secondary	Admission to neonatal intensive care unit or equivalent	Admission of infant to neonatal intensive care unit or equivalent	From time of birth to six weeks postnatal.
Secondary	Length of time from membrane sweep to birth of baby.	Length of time from membrane sweep to birth of baby .	From time of membrane sweep to birth of baby (up to 4 weeks)
Secondary	Length of time from formal induction of labour to birth of baby.	Length of time from formal induction of labour to birth of baby.	From time of formal induction of labour to birth of baby (up to 2 weeks)
Secondary	Overall length of maternal hospital stay	Overall length of maternal hospital stay	From time of randomisation to six weeks postnatal (up to 11 weeks).
Secondary	Length of infant stay in neonatal intensive care unit or equivalent	Length of infant stay in neonatal intensive care unit or equivalent	From time of birth to six weeks postnatal.